免疫療法の実績

gr1

出典:Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features; Daniel M. Geynisman, European Urology, Vol(68)5,Nov 2015,p912-914

opdivo2

出典:PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma, Nghiem P.T, Bhatia S,Lipson E.J, et al.N EngJ.med April,2016

opdivo3

出典:Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma; Hamid O., Robert C., Daud A., et al.N Engl J Med 2013;369:134-144

opdivo6

出典:Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma; Hamid O., Robert C., Daud A., et al.N Engl J Med 2013;369:134-144

opdivo5

出典:Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma; Hamid O., Robert C., Daud A., et al.N Engl J Med 2013;369:134-144